Optimizing the dose of pre-pandemic influenza vaccines to reduce the infection attack rate
about
Major issues and challenges of influenza pandemic preparedness in developing countriesEnhanced immunogenicity, mortality protection, and reduced viral brain invasion by alum adjuvant with an H5N1 split-virion vaccine in the ferretA systematic review to identify areas of enhancements of pandemic simulation models for operational use at provincial and local levels.Mitigating effects of vaccination on influenza outbreaks given constraints in stockpile size and daily administration capacity.The use of mathematical models to inform influenza pandemic preparedness and response.Mitigation approaches to combat the flu pandemic.Modeling influenza epidemics and pandemics: insights into the future of swine flu (H1N1).Preparedness for the spread of influenza: prohibition of traffic, school closure, and vaccination of children in the commuter towns of Tokyo.Estimating the incidence reporting rates of new influenza pandemics at an early stage using travel data from the source country.Influenza pandemic vaccines: spread them thin?The contribution of social behaviour to the transmission of influenza A in a human population.Does the effectiveness of control measures depend on the influenza pandemic profile?Effective, robust design of community mitigation for pandemic influenza: a systematic examination of proposed US guidance.Herd immunity and fatal cases of influenza among the population exposed to poultry and wild birds in Russian Asia in 2013-2014.Optimal dosing and dynamic distribution of vaccines in an influenza pandemic.Reproductive numbers, epidemic spread and control in a community of households.Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States.Strategies for mitigating an influenza pandemic with pre-pandemic H5N1 vaccines.Economic analysis of pandemic influenza vaccination strategies in Singapore.One versus two doses: What is the best use of vaccine in an influenza pandemic?Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures.Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies.Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.Vaccination against influenza: role and limitations in pandemic intervention plans.Modeling the impact of air, sea, and land travel restrictions supplemented by other interventions on the emergence of a new influenza pandemic virus.Optimal vaccine allocation for the early mitigation of pandemic influenza.Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets.Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model.Quantifying the impact of immune escape on transmission dynamics of influenza.Mechanistic Models of Infectious Disease and Their Impact on Public Health.Fractional dosing of yellow fever vaccine to extend supply: a modelling study.Improving vaccine trials in infectious disease emergencies.Spatial considerations for the allocation of pre-pandemic influenza vaccination in the United States
P2860
Q24646958-664871F0-31EF-4D63-A8FF-6A7D1ED7846BQ27336156-59BBC6D7-4CF6-443C-9448-71E405A1BD41Q30224678-D0378A12-61EF-4BE4-AB0C-E605C5FABFFAQ30226457-5F012537-2C8D-42CD-A94A-36043BB2558FQ30226500-D858E62D-BEBC-47DF-917C-AA995ADF0C0FQ30227246-56E89AB1-70E7-4AB6-934C-5724AD9EE457Q30227845-E6E17861-BD08-4FAB-803C-1346C9420006Q30228958-990BFB65-7524-4D55-8D03-9E1E0065E07DQ30354261-8D2B8BF5-8BFE-4156-8868-4D3E15CD2CA8Q30362440-1A5CE811-D3BA-4789-948C-131F7B15BE57Q30364008-CECF6811-F939-4ED7-9851-2BF862E99D63Q30367271-D6A88451-119B-4222-9B94-4CA19ACF3CC4Q30370409-E86E2CB8-73B9-4C3A-92BE-0994360C7EDCQ30376005-81FE0EF4-F18B-473B-81ED-1817B23F7F7BQ30376523-26D5AB2B-1104-42B9-8A7C-5543DC724D29Q30378453-93EB3AF8-0450-49A6-8C6A-96886600A1D1Q30379858-7F293B8E-B17C-404B-A4A7-21057C8345A1Q30380700-9A72A03B-0D50-48A6-B042-E659C97BC9A4Q30380974-A7714827-2CDE-41D4-83D7-FD804923273BQ30382026-4566398E-DD48-4A34-8E65-349AFD9DBE9AQ30386212-D0D1E07E-5C65-49FF-AF7A-536B5BC4C30FQ30388996-28D9C851-9EB9-4E35-BD3C-9C5C90BC1F3CQ30399700-BB5F80C1-7721-49CC-8398-16F8B3A1B7A8Q30421562-82DDD6A6-A2D1-4B2F-B1C5-7CD50FFB8DBEQ30423708-063E72B5-DD9D-49A1-B90E-283ED036F597Q30428994-46B5C469-4158-4EEF-ABF5-9B8AEE00D010Q33396140-975A381F-3294-48CE-B789-3CCF9D499190Q33538308-4ED082EF-2389-4301-B768-2B263CF02410Q35012029-CB0C5CB7-9A03-4096-A1C1-1E9049CC3064Q37221114-4C7F945C-997B-4043-9F40-97EEDBD921A2Q39192916-DC5E4FF8-7DEF-45B9-94EC-24DC1BC13809Q39433750-17BC9F57-D365-4F3B-A328-6014A73B6F81Q57113147-0B4C87E8-512A-4DCE-B7DC-BFEE53647A33
P2860
Optimizing the dose of pre-pandemic influenza vaccines to reduce the infection attack rate
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Optimizing the dose of pre-pan ...... duce the infection attack rate
@ast
Optimizing the dose of pre-pan ...... duce the infection attack rate
@en
type
label
Optimizing the dose of pre-pan ...... duce the infection attack rate
@ast
Optimizing the dose of pre-pan ...... duce the infection attack rate
@en
prefLabel
Optimizing the dose of pre-pan ...... duce the infection attack rate
@ast
Optimizing the dose of pre-pan ...... duce the infection attack rate
@en
P2860
P1433
P1476
Optimizing the dose of pre-pan ...... duce the infection attack rate
@en
P2093
Steven Riley
P2860
P356
10.1371/JOURNAL.PMED.0040218
P407
P577
2007-06-01T00:00:00Z